



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Alan Garen *et al.*

Serial No.: 10/030,203

Filed: December 31, 2001

For: Neovascular-Targeted Immunoconjugates

Atty. Docket No.: 006337.00004

Group Art Unit: 1642

Examiner: TBD

PATENT
RECEIVED
JUL 01 2003
TECH CENTER 1600/2900
P# 10

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313

Sir:

Submitted herewith are a Form PTO-1449 and a copy of the documents listed therein.

It is requested that the Examiner make his consideration of these documents formally of record with his initial action.

Since this Information Disclosure Statement is being filed before issuance of a first Office Action on the merits under 37 C.F.R. 1.97(b), it is submitted that no fee or certification is required. However, if a fee is required, please charge our Deposit Account No. 19-0733

Respectfully submitted,

BANNER & WITCOFF, LTD.

Date: June 30, 2003


By: _____

Sarah A. Kagan

Registration No. 32,141

Customer No. 22907
Banner & Witcoff, Ltd.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/030,203
Filing Date	December 31, 2001
First Named Inventor	Alan Garen
Group Art Unit	1642
Examiner Name	TBD
Attorney Docket Number	006337.00004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		E. WILMES et al., "Versuche zur Herstellung menschlicher monoklonaler Antikörper gegen Melanome unter Verwendung zervikaler Lymphknoten," <u>Laryng. Rhinol. Otol.</u> , (1987), Vol. 66, pp. 144-148.	
		JAMIE K. SCOTT and GEORGE SMITH, "Searching for Peptide Ligands with an Epitope Library," <u>Science</u> , (July 27, 1990), Vol. 249, pp. 386-390.	
		JAMES D. MARKS et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage," <u>J. Med Biol.</u> , (1991), Vol. 222, pp. 581-597.	
		GREG WINTER and CESAR MILSTEIN, "Man-made Antibodies," <u>Nature</u> , (January 24, 1991), Vol. 349, pp. 293-299.	
		JAMES D. MARKS et al., "By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <u>Bio/Technology</u> , (July 1992), Vol. 10, pp. 779-783.	
		G. DEL BINO et al., "Apoptotic Cell Death Triggered by Camptothecin or Teniposide. The Cell Cycle Specificity and Effects of Ionizing Radiation," <u>Cell Prolif.</u> , (1992), Vol. 25, pp. 537-548.	
		ANDREW D. GRIFFITHS et al., "Human Anti-self Antibodies with High Specificity from Phage Display Libraries," <u>The EMBO Journal</u> , (1993), Vol. 12, No. 2, pp. 725-734.	
		LEE H. PAI and IRA PASTAN, "Immunotoxin Therapy for Cancer," <u>JAMA</u> , (January 6, 1993), Vol. 269, No. 1, pp. 78-81.	
		DAVE S.B. HOON et al., "Molecular Cloning of a Human Monoclonal Antibody Reactive to Ganglioside Antigen on Human Cancers," <u>Cancer Research</u> , (November 1, 1993), Vol. 53, pp. 5244-5250.	
		MARIA-ANA GHETIE and ELLEN S. VITETTA, "Recent Developments in Immunotoxin Therapy," <u>Current Opinion in Immunology</u> , (1994), Vol. 6, pp. 707-714.	
		BRENDA L. HALL et al., "Establishment, Molecular Rescue, and Expression of 123AV16-1, a Tumor-reactive Human Monoclonal Antibody," <u>Cancer Research</u> , (1994), Vol. 54, pp. 5178-5185.	
		XIAOHONG CAI and ALAN GAREN, "Anti-melanoma Antibodies from Melanoma Patients Immunized with Genetically Modified Autologous tumor cells: Selection of Specific Antibodies from Single-Chain Fv Phage Fusion Libraries," <u>Proc. Natl. Acad. Sci. USA</u> , (1995), Vol. 92, pp. 6537-6541.	
		MARTIN FRIEDLANDER et al., "Involvement of Integrins $\alpha_3\beta_3$ and $\alpha_5\beta_3$ in Ocular Neovascular Diseases," <u>Proc. Natl. Acad. Sci. USA</u> , (September, 1996), Vol. 93, pp. 9764-9769.	
		XIAOHONG CAI and ALAN GAREN, "A Melanoma-Specific V _H Antibody Cloned from a Fusion Phage Library of a Vaccinated Melanoma Patient," <u>Proc. Natl. Acad. Sci. USA</u> , (June 1996), Vol. 93, pp. 6280-6285.	


Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/030,203
Filing Date	December 31, 2001
First Named Inventor	Alan Garen
Group Art Unit	1642
Examiner Name	TBD
Attorney Docket Number	006337.00004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CRAIG D. DICKINSON, "Identification of Surface Residues Mediating Tissue Factor Binding and Catalytic Function of the Serine Protease Factor VIIa", <u>Proc. Natl. Acad. Sci. USA</u> , (December 1996), Vol. 93, pp. 14379-14384.	
		XIAOHONG CAI and ALAN GAREN, "Comparison of Fusion Phage Libraries Displaying V _H or Single-chain Fv Antibody Fragments Derived from the Antibody Repertoire of a Vaccinated Melanoma Patient as a Source of Melanoma-Specific Targeting Molecules," <u>Proc. Natl. Acad. Sci. USA</u> , (August 1997), Vol. 94, pp. 9261-9266.	
		HENNIE R. HOOGENBOOM, "Designing and Optimizing Library Selection Strategies for Generating High-affinity Antibodies," <u>Tibtech</u> , (February 1997), Vol. 15, pp. 62-70.	
		BAIYANG WANG, et al, "Human Single-chain Fv Immunoconjugates Targeted to a Melanoma-associated Chondroitin Sulfate Proteoglycan Mediate Specific Lysis of Human Melanoma Cells by Natural Killer Cells and Complement," <u>Proc. Natl. Acad. Sci. USA</u> , (February 1999), Vol. 96, pp. 1627-1632.	
		DJ CHAPLIN and GJ DOUGHERTY, "Tumour Vasculature as a Target for Cancer Therapy," <u>British Journal of Cancer</u> , (1999), Vol. 80 (Supplement 1), pp. 57-64.	
		ZOLTAN SZEKANECZ et al., "Angiogenesis in Rheumatoid Arthritis: Pathogenic and Clinical Significance," <u>J Invest. Med.</u> , (1998), Vol. 46, pp. 27-41.	
		GARY S. FIRESTEIN, "Starving the Synovium: Angiogenesis and Inflammation in Rheumatoid Arthritis," <u>The Journal of Clinical Investigation</u> , (January 1999), Vol. 103, Number 1, pp. 3-4.	
		CHRIS M. STORGARD et al., "Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an $\alpha v \beta_3$ Antagonist," <u>The Journal of Clinical Investigation</u> , (1999), Vol. 103, Number 1, pp. 47-54.	
		HENRY J. KAPLAN et al., "Fas Ligand (CD95 Ligand) Controls Angiogenesis Beneath the Retina," <u>Nature Medicine</u> , (March 1999), Vol. 5, Number 3, pp. 292-297.	
		GLENN DRANOFF and RICHARD C. MULLIGAN, "Gene Transfer as Cancer Therapy," <u>Advances in Immunology</u> , Vol. 58, (1995), pp. 417-454.	
		E. HABER and F.F. RICHARDS, "The Specificity of Antigenic Recognition of Antibody Heavy Chain," <u>Proc. R. Soc. Lond. B. Biol. Sci.</u> , (1996), Vol. 166, pp. 176-187.	
		ZHIWEI HU and ALAN GAREN, "Intratympanic Injection of Adenoviral Vectors Encoding Tumor-targeted Immunoconjugates for Cancer Immunotherapy," <u>Proc. Natl. Acad. Sci.</u> , (August 1, 2000), Vol. 97, No. 16, pp. 9221-9225.	
		ZHIWEI HU, et al, "Targeting Tissue Factor on Tumor Vascular Endothelial Cells and Tumor Cells for Immunotherapy in Mouse Models of Prostatic Cancer", <u>Proc. Natl. Acad. Sci.</u> , (October 9, 2001), Vol. 98, No. 21, pp. 12180-12185.	
		PURAN S. BORA, et al., "Immunotherapy for Choroidal Neovascularization of a Laser-induced Mouse Model Simulating Exudative (wet) Macular Degeneration," <u>Proc. Natl. Acad. Sci.</u> , <u>Proc. Natl. Acad. Sci. USA</u> , (March 4, 2003), Vol. 100, No. 5, pp. 2579-2684.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number 10/030,203

Filing Date December 31, 2001

First Named Inventor Alan Garen

Group Art Unit 1642

Examiner Name TBD

Total Number of Pages in This Submission

Attorney Docket Number 006337.00004

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Response

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/
Incomplete Application

☐ Response to Missing
Parts under 37 CFR
1.52 or 1.53

☐ Assignment Papers
(for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a
Provisional Application

☐ Power of Attorney, Revocation
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

☐ After Allowance Communication to
Group

☐ Appeal Communication to Board of
Appeals and Interferences

☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s)
(please identify below):

PTO 1449; References

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Sarah A. Kagan, Reg. No. 32,141

Signature

Sarah A. Kagan

Date

June 30, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: _____

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.